{ "@graph": [    { "@id": "http://linked.opendata.cz/resource/ATC/C",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "CARDIOVASCULAR SYSTEM" , "@language" : "en" } ,        { "@value" : "Kardiovaskul\u00E1rn\u00ED syst\u00E9m" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "L\u00E9\u010Diva ovliv\u0148uj\u00EDc\u00ED renin-angiotenzinov\u00FD syst\u00E9m" , "@language" : "cs" } ,        { "@value" : "AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09A",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "ACE inhibitory, samotn\u00E9" , "@language" : "cs" } ,        { "@value" : "ACE INHIBITORS, PLAIN" , "@language" : "en" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09A" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09AA",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "ACE inhibitors, plain" , "@language" : "en" } ,        { "@value" : "ACE inhibitory, samotn\u00E9" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09AA" } ] } ,    { "@id": "http://linked.opendata.cz/resource/ATC/C09AA02",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/ATCConcept" ] ,      "http://www.w3.org/2004/02/skos/core#broaderTransitive" : [ "http://linked.opendata.cz/resource/ATC/C" ,        "http://linked.opendata.cz/resource/ATC/C09" ,        "http://linked.opendata.cz/resource/ATC/C09A" ,        "http://linked.opendata.cz/resource/ATC/C09AA" ] ,      "http://purl.org/dc/terms/title" : [ { "@value" : "Enalapril" , "@language" : "en" } ,        { "@value" : "Enalapril" , "@language" : "cs" } ] ,      "http://www.w3.org/2004/02/skos/core#notation" : [ { "@value" : "C09AA02" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0331398",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/Ingredient" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Enalapril maleate" , "@language" : "en" } ,        { "@value" : "Enalapril maleate" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPharmacologicalAction" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001456" ,        "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001207" ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product/ENAP-2-5-MG",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProduct" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasActiveIngredient" : [ "http://linked.opendata.cz/resource/drug-encyclopedia/ingredient/M0331398" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "ENAP 2,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09AA02" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMedicinalProductPackaging" : [ "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0006550" ,        "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0059976" ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001207",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Angiotensin-converting enzyme inhibitors" , "@language" : "en" } ,        { "@value" : "Inhibitory angiotenzin konvertuj\u00EDc\u00EDho enzymu" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/drug-encyclopedia/pharmacological-action/M0001456",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/PharmacologicalAction" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "Antihypertenz\u00EDva" , "@language" : "cs" } ,        { "@value" : "Antihypertensive agents" , "@language" : "en" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/description" : [ { "@value" : "Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.     " , "@language" : "en" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0006550",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "ENAP 2,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09AA02" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC102998_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "100" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "2.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "- l\u00E9\u010Dba hypertenze;\n- l\u00E9\u010Dba symptomatick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED;\n- prevence symptomatick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED u pacient\u016F s asymptomatickou dysfunkc\u00ED lev\u00E9 komory (ejek\u010Dn\u00ED frakce \u2264 35%).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL NOB 100X2.5MG" , "@language" : "cs" } ] } ,    { "@id": "http://linked.opendata.cz/resource/sukl/medicinal-product-packaging/0059976",      "@type" : [ "http://linked.opendata.cz/ontology/drug-encyclopedia/MedicinalProductPackaging" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/title" : [ { "@value" : "ENAP 2,5 MG" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasATCConcept" : [ "http://linked.opendata.cz/resource/ATC/C09AA02" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndicationGroup" : [ { "@value" : "HYPOTENSIVA" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasSPCDocument" : [ "http://linked.opendata.cz/resource/sukl/spc/document/SPC102998_doc" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasPackagingSize" : [ { "@value" : "30" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRouteOfAdministration" : [ { "@value" : "Peror\u00E1ln\u00ED pod\u00E1n\u00ED" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasStrength" : [ { "@value" : "2.5MG" , "@type" : "http://www.w3.org/2001/XMLSchema#string" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasIndication" : [ { "@value" : "- l\u00E9\u010Dba hypertenze;\n- l\u00E9\u010Dba symptomatick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED;\n- prevence symptomatick\u00E9ho srde\u010Dn\u00EDho selh\u00E1n\u00ED u pacient\u016F s asymptomatickou dysfunkc\u00ED lev\u00E9 komory (ejek\u010Dn\u00ED frakce \u2264 35%).\n" , "@language" : "cs" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasRegistrationState" : [ "http://linked.opendata.cz/resource/sukl/registration-state/R" ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasResumedMarketingDate" : [ { "@value" : "2000-01-01" , "@type" : "http://www.w3.org/2001/XMLSchema#date" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasMaximalPrice" : [ { "@value" : 55.70999908447266 , "@type" : "http://www.w3.org/2001/XMLSchema#float" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasReimbursementAmount" : [ { "@value" : 18.17000007629395 , "@type" : "http://www.w3.org/2001/XMLSchema#float" } ] ,      "http://linked.opendata.cz/ontology/drug-encyclopedia/hasTitleSupplement" : [ { "@value" : "POR TBL NOB 30X2.5MG" , "@language" : "cs" } ] }] }